The CFTR modulator therapy ivacaftor (Kalydeco) may be safely used in the first year of life to treat the underlying cause of cystic fibrosis, latest results from the ARRIVAL study suggest. Currently listed on the PBS for use in children from 12-24 months of age, newly-published findings show the drug can be safely dosed in ...
Study supports use of ivacaftor in first year of life for children with CF
By Michael Woodhead
27 Oct 2020